文献速递淋巴瘤

R-MACLO-IVAM方案序贯维持治疗在初治套细胞淋巴瘤中诱导持久缓解:长期随访结果

R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
PubMed 文献 · Am J Hematol · 2021-04-07

两项临床试验长期联合结果:44例初治套细胞淋巴瘤患者接受R-MACLO-IVAM诱导后分别接受沙利度胺或利妥昔单抗维持治疗,中位随访7.2年,5年PFS 55.6%,5年OS 83.3%,中位OS未达到,长期治疗相关死亡率6.8%。

要点

  • R-MACLO-IVAM诱导后维持治疗在初治MCL中可获得持久缓解,无需ASCT巩固。
  • 44例患者中41例(93.2%)达完全缓解,5年PFS 55.6%,5年OS 83.3%。
  • 母细胞变异型患者(n=6)5年PFS仅20.8%、OS 60%,预后较差。

核心结论

  • R-MACLO-IVAM方案序贯维持治疗可有效诱导MCL长期缓解,且无需ASCT巩固。

研究设计与样本

  • 两项临床试验长期联合分析,共纳入44例初治MCL患者。
  • 前22例(UM-MCL1,NCT00450801)接受沙利度胺维持(200 mg每日至复发/不可耐受毒性)。
  • 后22例(UM-MCL2,NCT00878254)接受利妥昔单抗维持(375 mg/m2 IV每周×4,每6个月重复,共3年)。

主要发现

  • 全部44例中41例(93.2%)达完全缓解,2例(4.5%)达部分缓解,1例(2.3%)未评估缓解。
  • 中位随访7.2年(范围<1个月至16年),5年PFS为55.6%(95%CI:38.9%-69.4%),中位PFS 7.9年(95%CI:3.7-11年)。
  • 5年OS为83.3%(95%CI:68.1%-91.7%),中位OS未达到。
  • 母细胞变异型患者(n=6)5年PFS和OS分别为20.8%和60%。
  • 免疫化疗期间最常见不良事件为骨髓抑制,长期治疗相关死亡率为6.8%。

关键数值与推荐

  • R-MACLO-IVAM诱导方案具体剂量与给药方案原文未报告。
  • 沙利度胺维持剂量为200 mg每日,直至复发或不可耐受毒性。
  • 利妥昔单抗维持剂量为375 mg/m2 IV每周×4,每6个月重复,共3年。

临床怎么用

  • 对于初治MCL患者,可考虑R-MACLO-IVAM诱导后序贯沙利度胺或利妥昔单抗维持治疗,无需ASCT巩固。
  • 治疗期间需关注骨髓抑制,长期随访注意治疗相关死亡风险。
  • 母细胞变异型患者预后仍较差,需探索更优策略。

局限性

  • 样本量较小(44例),为两项临床试验的长期联合分析。
  • 非随机对照设计,两种维持治疗方案分属不同队列,无法直接比较。
  • 母细胞变异型亚组样本量仅6例,结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM-MCL1 ClinicalTrials.gov identifier NCT00450801) received maintenance with thalidomide (200 mg daily until relapse/intolerable toxicity) and a subsequent cohort of 22 patients (UM-MCL2 ClinicalTrials.gov identifier NCT00878254) received rituximab (375 mg/m2 IV weekly × 4, repeated every 6 months for 3 years). Considering all 44 patients, 41 (93.2%) achieved complete response (CR), two (4.5%) partial response (PR), and one (2.3%) was not evaluated for response. With a median follow up of 7.2 years (range < 1 month to 16 years), the 5-year progression-free survival (PFS) was 55.6% (95% CI: 38.9%-69.4%) and median PFS 7.9 years (95% CI: 3.7-11 years). The 5-year OS was 83.3% (95% CI: 68.1%-91.7%) and median OS was not reached. Patients with blastic variant (n = 6) had a 5-year PFS and OS of 20.8% and 60%, respectively. Myelosuppression was the most common adverse event during immunochemotherapy. Long-term treatment-related mortality was 6.8%. Note, R-MACLO-IVAM followed by maintenance therapy is an effective regimen to induce long-term remission in MCL without need for consolidation with ASCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Alderuccio JP, Saul EE, Iyer SG, et al. R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results. Am J Hematol. 2021. PMID: 33735476. doi:10.1002/ajh.26163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。